-
公开(公告)号：US20140205672A1
公开(公告)日：2014-07-24
申请号：US14158149
申请日：2014-01-17
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shigeo Yanai , Kazumichi Yamamoto
IPC: A61K9/24 , A61K31/4188
CPC classification number: A61K9/209 , A61K9/28 , A61K31/4188
Abstract: A controlled release composition for oral administration, which comprises a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring which may be substituted, or a salt thereof, and a hydrophilic polymer, or a controlled release composition for oral administration, wherein a core containing the physiologically active substance is coated with a coating layer containing a polymer, is provided.
Abstract translation: 一种用于口服给药的控释组合物，其包含生理活性物质，其为由下式表示的化合物：其中n为1〜3的整数，Ar为可被取代的芳香环，或其盐，以及 亲水性聚合物或用于口服给药的控释组合物，其中含有生理活性物质的核心被包含聚合物的涂层涂覆。
-
公开(公告)号：US12178981B2
公开(公告)日：2024-12-31
申请号：US16958388
申请日：2018-12-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Naoyuki Murata , Shigeo Yanai
Abstract: The present disclosure provides a safer novel opening system with highly broad utility for a blood-brain barrier (BBB), the opening system containing a combination of (1) nano-bubble water or nano-bubble aqueous solution containing nano-bubbles having an average diameter of not more than 200 nm, and (2) an ultrasound generating apparatus; a method for opening a BBB, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound; and a method for increasing BBB permeability of a drug, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound.
-
公开(公告)号：US09364438B2
公开(公告)日：2016-06-14
申请号：US14430956
申请日：2013-09-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Naoyuki Murata , Shigeo Yanai
CPC classification number: A61K9/1688 , A61K9/14 , A61K31/18 , A61K31/24
Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.
Abstract translation: 一种生产水溶性差的药物化合物的方法，包括将难溶于水的药物化合物的溶液与纳米气泡水溶液或纳米气泡水溶液混合，使难溶于水的药物化合物的晶体析出。 通过该方法得到的水溶性差的药物的结晶为微粒状，粒径分布更均匀，吸收性和可持续性优异。
-
公开(公告)号：US20150250728A1
公开(公告)日：2015-09-10
申请号：US14430956
申请日：2013-09-25
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Naoyuki Murata , Shigeo Yanai
CPC classification number: A61K9/1688 , A61K9/14 , A61K31/18 , A61K31/24
Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.
Abstract translation: 一种生产水溶性差的药物化合物的方法，包括将难溶于水的药物化合物的溶液与纳米气泡水溶液或纳米气泡水溶液混合，使难溶于水的药物化合物的晶体析出。 通过该方法得到的水溶性差的药物的结晶为微粒状，粒径分布更均匀，吸收性和可持续性优异。
-
-
-
Search Results
4
records
(took 0.013 seconds)
